Innovent and IASO Report Positive Data from BCMA CAR-T Trial
June 08, 2021 at 05:28 AM EDT
Innovent Bio of Suzhou and Nanjing IASO Bio posted positive data from a Phase I trial of their CAR-T therapy in multiple myeloma patients. CT103A, a BCMA CAR-T candidate, produced a 97% overall response rate (ORR) in 35 patients with relapsed/refractory multiple myeloma. Of these, 20 patients (57%) experienced a complete response. The two companies have already started a pivotal China Phase II trial in the same population. In February 2021, CT103A was granted Breakthrough Therapy Designation in China . More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //
